Life science CEOs' paychecks decrease as markets decline
When the markets are down, everyone is in the same boat, in theory -- however, former Ambu CEO Lars Marcher warns boards against unduly rewarding CEOs by changing pre-existing share-based programs.
by christian bundgaard, translated by daniel pedersen
When stock exchanges drop, bonusses in the shape of share-based programs for chief executives officers at companies like GN, Coloplast, and Lundbeck shrink, Danish financial media Finans reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck leads list of highest paid CEOs in Denmark
For subscribers
Genmab CEO lands USD 6.8m salary in 2021
For subscribers
.jpg&w=384&q=75)
